NodThera Looks To Compete In Long-Awaited Inflammasome Field With Parkinson’s Therapy

Will Face Competition From Roche

 
• By Andrew McConaghie
Brain scan
NodThera has chosen Parkinson's disease to be its first target with NT-0796. • Source: Shutterstock

More from Immunological

More from Therapy Areas